Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Mar 25

PMID 35329831

Authors

Eugenia Piragine

Davide Petri

Alma Martelli

Agata Janowska

Valentina Dini

Marco Romanelli

Vincenzo Calderone

Ersilia Lucenteforte

Affiliations

Soon will be listed here.

Abstract

Despite the large number of biologics currently available for moderate-to-severe psoriasis, poor adherence and persistence to therapy represent the main issues for both the clinical and economic management of psoriasis. However, the data about adherence and persistence to biologics in psoriasis patients are conflicting. Our aim was to produce summary estimates of adherence and persistence to biologics in adult patients with psoriasis. We performed a systematic review and meta-analysis of observational studies, searching two databases (PubMed and Embase). Sixty-two records met the inclusion criteria, and a meta-analysis was conducted on fifty-five studies. Overall, the proportion of adherent and persistent patients to biological therapy was 0.61 (95% confidence interval: 0.48-0.73) and 0.63 (0.57-0.68), respectively. The highest proportions were found for ustekinumab, while the lowest ones were found for etanercept. The proportions of adherence and persistence to biological drugs in psoriasis patients are sub-optimal. Notably, both proportions largely differ between drugs, suggesting that a more rational use of biologics might ensure better management of psoriasis.

Citing Articles

Biologic Treatment Adherence and Persistence in Patients with Palmoplantar Pustulosis: A Real-World, Claims-Based Study.

Feldman S, Gao R, Bohn R, Gray S, Deruaz-Luyet A, Wu J Adv Ther. 2025; .

PMID: 40025388 DOI: 10.1007/s12325-025-03122-w.

Factors Affecting Treatment Persistence in Japanese Patients with Psoriasis Prescribed Biologics: A Real-World Study Using an Insurance Claim Database.

Miyazaki C, Masuda J, Tsai P, Saeki H Dermatol Ther (Heidelb). 2024; 14(11):2999-3015.

PMID: 39407051 PMC: 11557743. DOI: 10.1007/s13555-024-01274-1.

Adherence, persistence and treatment switching in psoriasis.

Santoleri F, Musicco F, Fulgenzio C, Abrate P, Pestrin L, Pasut E Immunotherapy. 2024; 16(9):611-621.

PMID: 38651935 PMC: 11290367. DOI: 10.2217/imt-2023-0343.

Expression profile of mRNAs and miRNAs related to mitogen-activated kinases in HaCaT cell culture treated with lipopolysaccharide a and adalimumab.

Wojcik M, Plata-Babula A, Glowaczewska A, Sirek T, Orczyk A, Malecka M Cell Cycle. 2024; 23(4):385-404.

PMID: 38557266 PMC: 11174132. DOI: 10.1080/15384101.2024.2335051.

Healthcare Provider Administration of Biologics for Patients with Plaque Psoriasis: Literature Review and Clinical Considerations.

Brunner M, Holyoak K, DiRuggiero D J Clin Aesthet Dermatol. 2024; 16(12 Suppl 2):S20-S25.

PMID: 38464741 PMC: 10919952.

References

Giunta A, Ventura A, Chimenti M, Bianchi L, Esposito M . Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy. Drug Des Devel Ther. 2017; 11:1643-1651. PMC: 5472409. DOI: 10.2147/DDDT.S92128. View

Sawyer L, Malottki K, Sabry-Grant C, Yasmeen N, Wright E, Sohrt A . Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. PLoS One. 2019; 14(8):e0220868. PMC: 6693782. DOI: 10.1371/journal.pone.0220868. View

Khalid J, Fox K, Globe G, Maguire A, Chau D . Treatment patterns and therapy effectiveness in psoriasis patients initiating biologic therapy in England. J Dermatolog Treat. 2013; 25(1):67-72. DOI: 10.3109/09546634.2013.768762. View

Harding F, Stickler M, Razo J, DuBridge R . The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010; 2(3):256-65. PMC: 2881252. DOI: 10.4161/mabs.2.3.11641. View

Murage M, Tongbram V, Feldman S, Malatestinic W, Larmore C, Muram T . Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Prefer Adherence. 2018; 12:1483-1503. PMC: 6110273. DOI: 10.2147/PPA.S167508. View

Feldman S, Zhang J, Martinez D, Lopez-Gonzalez L, Marchlewicz E, Shrady G . Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status. J Dermatolog Treat. 2019; 32(2):203-211. DOI: 10.1080/09546634.2019.1698699. View

Parisi R, Iskandar I, Kontopantelis E, Augustin M, Griffiths C, Ashcroft D . National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020; 369:m1590. PMC: 7254147. DOI: 10.1136/bmj.m1590. View

Craig S, Warren R . Ixekizumab for the treatment of psoriasis: up-to-date. Expert Opin Biol Ther. 2020; 20(6):549-557. DOI: 10.1080/14712598.2020.1729736. View

Esposito M, Gisondi P, Cassano N, Ferrucci G, Del Giglio M, Loconsole F . Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol. 2013; 169(3):666-72. DOI: 10.1111/bjd.12422. View

10.

Lee S, Xie L, Wang Y, Vaidya N, Baser O . Evaluating the Effect of Treatment Persistence on the Economic Burden of Moderate to Severe Psoriasis and/or Psoriatic Arthritis Patients in the U.S. Department of Defense Population. J Manag Care Spec Pharm. 2018; 24(7):654-663. PMC: 10398301. DOI: 10.18553/jmcp.2018.24.7.654. View

11.

Feldman S, Evans C, Russell M . Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. J Dermatolog Treat. 2005; 16(1):37-42. DOI: 10.1080/09546630510025941. View

12.

Feldman S, Zhao Y, Navaratnam P, Friedman H, Lu J, Tran M . Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015; 21(3):201-9. PMC: 10397683. DOI: 10.18553/jmcp.2015.21.3.201. View

13.

Ergen E, Yusuf N . Inhibition of interleukin-12 and/or interleukin-23 for the treatment of psoriasis: What is the evidence for an effect on malignancy?. Exp Dermatol. 2018; 27(7):737-747. PMC: 6023723. DOI: 10.1111/exd.13676. View

14.

Hsu D, Gniadecki R . Patient Adherence to Biologic Agents in Psoriasis. Dermatology. 2016; 232(3):326-33. DOI: 10.1159/000444581. View

15.

Yeung H, Wan J, Van Voorhees A, Callis Duffin K, Krueger G, Kalb R . Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol. 2012; 68(1):64-72. PMC: 3488143. DOI: 10.1016/j.jaad.2012.06.035. View

16.

Choi C, Choi J, Kim B, Youn S . Economic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe Psoriasis. Ann Dermatol. 2018; 30(2):179-185. PMC: 5839889. DOI: 10.5021/ad.2018.30.2.179. View

17.

Campi P, Benucci M, Manfredi M, Demoly P . Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists. Curr Opin Allergy Clin Immunol. 2007; 7(5):393-403. DOI: 10.1097/ACI.0b013e3282ef96df. View

18.

Jacobi A, Rustenbach S, Augustin M . Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis. Int J Dermatol. 2015; 55(3):296-302. DOI: 10.1111/ijd.12879. View

19.

Bhosle M, Feldman S, Camacho F, Whitmire J, Nahata M, Balkrishnan R . Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. J Dermatolog Treat. 2006; 17(5):294-301. DOI: 10.1080/09546630600954594. View

20.

Iskandar I, Warren R, Lunt M, Mason K, Evans I, Mcelhone K . Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2017; 138(4):775-784. PMC: 5869053. DOI: 10.1016/j.jid.2017.09.044. View